AstraZeneca has renewed its participation in BioWisdom's Safety Intelligence Program for another three years.
Financial terms of the renewed agreement were not disclosed.
The companies have worked together since 2006, when AZ began exploring BioWisdom's Sofia to create a knowledgebase from a variety of texts in structured and unstructured formats.
In 2007 AZ joined BioWisdom's Safety Intelligence Program, an "intelligence system" for analyzing publicly available drug safety and toxicity data. The scope of the collaboration was extended in 2009 to AZ's internal toxicology reports (BI 04/17/2009).
SIP provides researchers with access to structured information from publicly accessible sources and enables searching, retrieval, and analysis of prior knowledge in toxicology.
David Cook, associate director of global safety assessment at AstraZeneca, said SIP provides AZ's scientists with access to both internal and public toxicology information and that this "knowledge is a key part of our strategies to improve the early identification and understanding of safety in our projects."